Solving the Challenges in Developing Next Generation Neuropsychiatric Therapeutics – Neuropsychiatric Drug Development
Globally it’s estimated 1 in 5 people suffer from neuropsychiatric disorders. This figure, combined with drugs that are showing little or no response is making neuropsychiatric disorders a huge unmet clinical need.
Drug development within neuropsychiatry has been stifled for decades by a lack of scientific progress in understanding the brain and costly and challenging clinical trials.
The tide is now starting to turn. Rapid scientific progress in identifying novel targets, discovering differentiated mechanisms of drug action and our ability to develop ‘fast acting’ therapeutics has brought renewed enthusiasm to the field and investment is pouring in.
Yet the lack of translatable animal models, costly clinical trials and difficulties in meeting clinical endpoints are preventing the field moving forward.
Neuropsychiatric Drug Development Summit will enable you to solve the challenges in bringing next generation neuropsychiatric therapeutics to market.
With an emphasis on depressive disorders, this industry focused forum will allow you to explore novel targets and mechanisms of action, address factors for mitigating and eliminating risk in clinical trials and evaluate the preclinical and clinical biomarker landscape to more robustly translate preclinical results in the clinic.
Join your peers at NDD to be part of the cross-industry discussion on latest developments, insights and science to elevate clinically effective neuropsychiatric therapeutic pipelines
“ I was impressed by many of the speakers and learnt a significant amount, which I was able to bring back to our discovery team.” Stephen Krause, Senior Principal Scientist, Eisai
“Excellent networking and learning opportunity for pharma scientists.”Matthew Kennedy, Director, Merck
“Essentially every speaker was excellent. A very informative and thought provoking series of presentations” National Institute Neurologic Disease & Stroke